GNA13抗体

+ +

•  

   

     Gel: 15%SDS-PAGE, Lysate: 40 μg, Lane 1-5: A172 cells, 293T cells, mouse kidney tissue, human testis tissue, Human brain malignant glioma tissue, Primary antibody: P00385(GNA13 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P00385(GNA13 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P00385(GNA13 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of GNA13 Antibody**

GNA13 (Guanine Nucleotide-Binding Protein Subunit Alpha-13) is a member of the Gα12/13 subfamily of heterotrimeric G-protein alpha subunits, which play critical roles in transmitting signals from G-protein-coupled receptors (GPCRs) to intracellular effector pathways. GNA13 is involved in regulating diverse cellular processes, including cell proliferation, migration, cytoskeletal reorganization, and apoptosis, primarily through activation of Rho GTPase signaling pathways such as RhoA. Dysregulation of GNA13 has been implicated in cancer progression, cardiovascular diseases, and immune disorders, with studies linking its overexpression or hyperactivation to enhanced tumor invasiveness, metastasis, and poor clinical outcomes.

GNA13 antibodies are essential tools for investigating the expression, localization, and functional roles of GNA13 in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP) to study protein levels, tissue distribution, and interaction partners. Specificity is a key consideration, as GNA13 shares homology with other Gα subunits (e.g., GNA12), necessitating rigorous validation via knockout controls or siRNA-based silencing. Some antibodies target unique epitopes within conserved domains, such as the GTP-binding region or C-terminal tail, to ensure precise detection.

Research utilizing GNA13 antibodies has advanced understanding of its role in diseases and highlighted its potential as a therapeutic target, particularly in cancers with aberrant GPCR-Rho signaling. Reliable antibodies remain crucial for unraveling the complex mechanisms governed by GNA13 in health and disease.